<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291885</url>
  </required_header>
  <id_info>
    <org_study_id>03.18</org_study_id>
    <nct_id>NCT04291885</nct_id>
  </id_info>
  <brief_title>Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma</brief_title>
  <acronym>I-MAT</acronym>
  <official_title>A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melanoma and Skin Cancer Trials Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melanoma and Skin Cancer Trials Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in&#xD;
      patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as&#xD;
      adjuvant immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The I-MAT trial is a phase II, prospective, randomised, placebo-controlled,&#xD;
      multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC).&#xD;
      Participants on the trial will receive either avelumab or placebo for 6 months. The primary&#xD;
      aim of the I-MAT trial is to develop an effective, well-tolerated adjuvant immunotherapy&#xD;
      regimen for patients with stage I-III MCC, following local and regional treatment options&#xD;
      which includes surgery and/or radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival (RFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Recurrence-free survival (RFS) as the primary endpoint, is anticipated to be analysed over an average planned follow-up of 3.5 years. An analysis of RFS at the 24 month time point of follow-up will also be conducted as it is anticipated that the minimum follow-up for participants will be 24 months and the sample size rationale utilises RFS rates at 24 months in historical controls. RFS is defined as the time from treatment initiation until the first date of any signs or symptoms of recurrence of tumour.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Overall survival rates at 12 and 24 months. Overall survival is defined as the time from treatment initiation to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (DSS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Disease-specific survival at 24 months from treatment initiation. Disease-specific survival is the percentage of participants who have not died from Merkel Cell Carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of loco-regional failure free survival (LRFFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of loco-regional failure free survival (LRFFS) is defined as the time from treatment initiation to the first recurrence of the loco-regional tumour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival (DMFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>DMFS is defined as the time from treatment initiation to the first evidence of distant metastatic disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicity and tolerability as assessed by NCI CTCAE v5.0</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of treatment-related adverse events (AEs). Safety will be measured by serious adverse events (SAEs) and AEs assessed as per NCI CTCAE v5.0, including immune-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life (QoL) as assessed by FACT-M questionnaire</measure>
    <time_frame>24 Months</time_frame>
    <description>FACT-M form (version 4) will be utilised. This will include patient-reported questions relating to physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and additional patient concerns which are measured from 0-4 (Not at all - Very Much).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Merkel cell polyomavirus positivity in stage I-III Merkel cell carcinoma</measure>
    <time_frame>24 Months</time_frame>
    <description>To identify Merkel cell polyomavirus MCPyV virus status. To correlate viral aetiology-rate of Merkel cell polyomavirus (MCPyV) positivity in pathology specimens in stage I-III Merkel cell carcinoma with outcome from adjuvant treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlating whole exome sequencing (WES) and ribonucleic acid (RNA) expression with immunotherapy response and outcomes in early stage MCC</measure>
    <time_frame>24 Months</time_frame>
    <description>To evaluate the relationship between somatic mutations in cancer genes or the total mutation burden of the cancer with immunotherapy response and outcome following adjuvant therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlating immune infiltrates by multiplex immunohistochemistry (IHC) with survival endpoints</measure>
    <time_frame>24 Months</time_frame>
    <description>To address whether immune infiltrates and PD-L1 expression are associated with survival.</description>
  </other_outcome>
  <other_outcome>
    <measure>Utility of circulating biomarkers in predicting recurrence in early stage MCC</measure>
    <time_frame>24 Months</time_frame>
    <description>To identify predictive biomarkers for response and resistance to immunotherapy in patients with stage I-III MCC using archival tissue and peripheral blood.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Merkel Cell Carcinoma, Stage I</condition>
  <condition>Merkel Cell Carcinoma, Stage II</condition>
  <condition>Merkel Cell Carcinoma, Stage III</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Carcinoma Neuroendocrine Skin</condition>
  <arm_group>
    <arm_group_label>Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab IV infusion</description>
    <arm_group_label>Avelumab</arm_group_label>
    <other_name>anti-PD-L1</other_name>
    <other_name>Bavencio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed Merkel cell carcinoma (MCC) which is either:&#xD;
&#xD;
               -  clinical stage I (pathological stage I MCC patients are not eligible for the&#xD;
                  study);&#xD;
&#xD;
               -  clinical or pathological stage II (including IIA and IIB);&#xD;
&#xD;
               -  clinical or pathological stage III (including IIIA and IIIB).&#xD;
&#xD;
          2. Absence of distant metastatic disease on baseline 18-Fludeoxyglucose (18FDG) -&#xD;
             Positron Emission Tomography (PET) / Computed Tomography (CT) scan.&#xD;
&#xD;
          3. 18 years of age or older.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) of 0 - 2.&#xD;
&#xD;
          5. Willing and able to provide written informed consent and comply with all study&#xD;
             requirements.&#xD;
&#xD;
          6. Adequate haematological, liver and renal function as determined by the screening&#xD;
             laboratory values outlined in the protocol obtained within 14 days prior to&#xD;
             randomisation.&#xD;
&#xD;
          7. Agreeable to collection of archival tumour material. Where possible, the most recently&#xD;
             acquired tumour specimen should be provided.&#xD;
&#xD;
          8. Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test within 72 hours prior to the start of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that&#xD;
             required treatment with systemic immunosuppressive treatments, which may suggest&#xD;
             significant risk for immune-related adverse events.&#xD;
&#xD;
          2. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.&#xD;
&#xD;
          3. Previous cancer immunotherapy, specifically interferon, anti-CD137, or anti-CTLA-4&#xD;
             antibody or any other antibody or drug specifically targeting T cell co-stimulation or&#xD;
             checkpoint pathways are not permitted.&#xD;
&#xD;
          4. Prior treatment with other immune-modulating agents that was within fewer than 28 days&#xD;
             prior to the first dose of Avelumab.&#xD;
&#xD;
          5. Active infection requiring antibiotics within 7 days of study entry.&#xD;
&#xD;
          6. Active tuberculosis.&#xD;
&#xD;
          7. Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          8. Uncontrolled infection with hepatitis B or hepatitis C virus (HBV or HCV) infection;&#xD;
             Patients with previously successfully treated HCV, with positive anti-HCV antibody but&#xD;
             undetectable (HCV) ribonucleic acid (RNA) levels are allowed on trial.&#xD;
&#xD;
          9. Current use of immunosuppressive medication, except for the following: a. intranasal,&#xD;
             inhaled, topical steroids, or local steroid injection ; b. systemic corticosteroids at&#xD;
             physiologic doses â‰¤ 10 mg/day of prednisone or equivalent; c. steroids as&#xD;
             premedication for hypersensitivity reactions&#xD;
&#xD;
         10. Any systemic anti-cancer treatment (chemotherapy, targeted systemic therapy)&#xD;
             investigational or standard of care, within 28 days of the first dose of Avelumab or&#xD;
             planned to occur during the study period. Patients receiving bisphosphonates or&#xD;
             denosumab will not be excluded.&#xD;
&#xD;
         11. Pregnant or breastfeeding.&#xD;
&#xD;
         12. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced&#xD;
             pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic&#xD;
             organising pneumonia), or evidence of active pneumonitis on screening chest CT scan).&#xD;
&#xD;
         13. Uncontrolled cardiac disease including not limited to symptomatic congestive heart&#xD;
             failure, unstable angina pectoris, life-threatening cardiac arrhythmia&#xD;
&#xD;
         14. Known prior severe hypersensitivity to investigational product or any component in its&#xD;
             formulations, including known severe hypersensitivity reactions to monoclonal&#xD;
             antibodies (NCI CTCAE v5 Grade 3).&#xD;
&#xD;
         15. Use of live attenuated vaccines within 28 days of first dose of Avelumab.&#xD;
&#xD;
         16. Any acute or chronic psychiatric problems that, in the opinion of the Investigator,&#xD;
             make the patient ineligible for participation due to compliance concerns.&#xD;
&#xD;
         17. Patients with prior allogeneic stem cell or solid organ transplantation.&#xD;
&#xD;
         18. Patients who are involuntarily incarcerated.&#xD;
&#xD;
         19. No evidence of other malignancy in the past 3 years, with exception of tumours with&#xD;
             negligible risk of metastasis or death.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Xu, MBBS, FRACP</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Alexandra Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanoma and Skin Cancer Trials Ltd Project officer</last_name>
    <phone>+61 3 9903 9022</phone>
    <email>imat@masc.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Stephen Begbie</last_name>
      <email>Stephen.Begbie@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Jenny Lee</last_name>
      <phone>0293831014</phone>
      <email>Jenny.Lee@lh.org.au</email>
    </contact>
    <investigator>
      <last_name>Dr Jenny Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Georgina Long</last_name>
      <phone>0299117336</phone>
      <email>Georgina.Long@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Prof Georgina Long</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A/Prof Alexander Guminski</last_name>
      <phone>0299265020</phone>
      <email>Alexander.Guminski@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>A/Prof Alexander Guminski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Michael Veness</last_name>
      <phone>0288905200</phone>
      <email>Michael.Veness@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Prof Michael Veness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ina Nordman</last_name>
      <phone>0240143190</phone>
      <email>Ina.Nordman@calvarymater.org.au</email>
    </contact>
    <investigator>
      <last_name>Dr Ina Nordman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Morteza Aghmesheh</last_name>
      <phone>02 4228 6200</phone>
      <email>Morteza.Aghmesheh@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Woman's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Melissa Eastgate</last_name>
      <phone>0736469917</phone>
      <email>Melissa.Eastgate@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dr Melissa Eastgate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Service, Bundaberg Base Hospital</name>
      <address>
        <city>Bundaberg</city>
        <state>Queensland</state>
        <zip>4670</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Craig Mulhall</last_name>
      <phone>07 41549900</phone>
      <email>WBHHS-Cancer-Care-Research@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Dr Joanne Tan</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Megan Lyle</last_name>
      <phone>0742267383</phone>
      <email>Megan.Lyle@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Dr Madhavi Dr Chilkuri</last_name>
      <phone>0744331801</phone>
      <email>Madhavi.Chilkuri@health.qld.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cancer Care Service, Hervey Bay Hospital</name>
      <address>
        <city>Hervey Bay</city>
        <state>Queensland</state>
        <zip>4655</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Hayden Christie</last_name>
      <phone>07 4325 6110</phone>
      <email>WBHHS-Cancer-Care-Research@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Dr Soe Yu Aung</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mackay Hospital and Health Service</name>
      <address>
        <city>Mackay</city>
        <state>Queensland</state>
        <zip>4740</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Zia Ansari</last_name>
      <phone>0748857952</phone>
      <email>Zia.Ansari@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Madhavi Chilkuri</last_name>
      <phone>0744331801</phone>
      <email>Madhavi.Chilkuri@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dr Madhavi Chilkuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A/Prof Victoria Atkinson</last_name>
      <phone>0731762111</phone>
      <email>victoria.atkinson@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dr Wen Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>A/Professor Victoria Atkinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Michael Brown</last_name>
      <phone>0883027827</phone>
      <email>MichaelP.Brown@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Prof Michael Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre Hobart</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Christina Moldovan</last_name>
      <phone>03 6240 2600</phone>
      <email>hobart.research@icon.team</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Mark Shackleton</last_name>
      <phone>0390763129</phone>
      <email>mark.shackleton@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Prof Mark Shackleton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A/Prof Shahneen Sandhu</last_name>
      <phone>0385595000</phone>
      <email>Shahneen.Sandhu@petermac.org</email>
    </contact>
    <investigator>
      <last_name>A/Prof Shahneen Sandhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

